| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/13/2005 | CN1636580A Medicine composition for treating coronary heart disease and its prepn process and use |
| 07/13/2005 | CN1636572A Compositions and methods for treatment of mitochondrial diseases |
| 07/13/2005 | CN1636566A Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| 07/13/2005 | CN1636563A 噻唑衍生物 Thiazole derivatives |
| 07/13/2005 | CN1636561A Use of at-1 receptor antagonist for treating diseases associated with an increase of at-1 receptors |
| 07/13/2005 | CN1210279C Thiazolo (4,5-D) pyrimidine compounds |
| 07/13/2005 | CN1210273C Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/13/2005 | CN1210270C Novel use of phenylheteroalkylamine derivatives |
| 07/13/2005 | CN1210266C Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methysulfonyl)amino]pyrimidin-5-yl]-(3R5S)-3,5-dihydroxyhept-6-enojc acid |
| 07/13/2005 | CN1210263C N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| 07/13/2005 | CN1210262C Method for preparing methylsulfonate trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperid-1-yl)-1-propanol |
| 07/13/2005 | CN1210256C Diacylhydrazine derivs |
| 07/13/2005 | CN1210251C Substituted nor bornylamion derivatives, method for production thereof, use thereof and medicaments containing said compounds |
| 07/13/2005 | CN1210250C Benzene derivatives, preparation method and pharmaceutical compositions containing same |
| 07/13/2005 | CN1210066C Cloning pigs using donor nuclei from differentiated cells |
| 07/13/2005 | CN1210048C Gingko leaf drop pill |
| 07/13/2005 | CN1210039C Total sanchinoside and ferulic acid composition for treating cardio-cerebral vascular disease and diabetes and its use |
| 07/13/2005 | CN1210036C Novel usage of Aspirin-DL-Lysine |
| 07/12/2005 | US6916927 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
| 07/12/2005 | US6916850 Pyruvate derivatives |
| 07/12/2005 | US6916848 Compounds for the treatment of metabolic disorders |
| 07/12/2005 | US6916847 Anticoagulants; thrombosis; cardiovascular disorders |
| 07/12/2005 | US6916838 1-benzylpyrazole-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 07/12/2005 | US6916834 Preparations and use of an Ah receptor ligand, 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 07/12/2005 | US6916832 Nitrogen compounds such as 8,9-dihydroxy-1,2,3,11b-tetrahydro-chromeno(4,3,2-de)isoquinoline hydrobromide, administered for prophylaxis of nervous system disorders |
| 07/12/2005 | US6916826 Substituted imidazo[1,2-a]pyridine derivatives |
| 07/12/2005 | US6916823 Method of treatment of dopamine-related dysfunction |
| 07/12/2005 | US6916817 Inhibitors of metalloproteinases |
| 07/12/2005 | US6916814 Methods of treating cytokine mediated diseases |
| 07/12/2005 | US6916813 (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
| 07/12/2005 | US6916811 Adenosine A2a receptor antagonists |
| 07/12/2005 | US6916810 αν integrin receptor antagonists |
| 07/12/2005 | US6916809 Heterocyclic acridone inhibitors of IMPDH enzyme |
| 07/12/2005 | US6916808 2-thio-4h-3, 1-benzoxazin-4-one derivatives for use as enzyme inhibitors |
| 07/12/2005 | US6916807 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 07/12/2005 | US6916804 Pyrimidine A2b selective antagonist compounds, their synthesis and use |
| 07/12/2005 | US6916629 Tissue factor pathway inhibitor-3 |
| 07/12/2005 | US6916625 Artery- and vein-specific proteins and uses therefor |
| 07/12/2005 | US6916303 Photoreduction method for hemoglobin-vesicle |
| 07/12/2005 | CA2341739C Quinolin-2-one derivatives useful as anticancer agents |
| 07/12/2005 | CA2323008C Pharmaceutically active compounds |
| 07/12/2005 | CA2137525C Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate |
| 07/07/2005 | WO2005061529A1 Peptide inhibiting angiontensin converting enzyme |
| 07/07/2005 | WO2005061492A1 Nitrogen-containing heterocyclic compounds and drugs comprising the same as the active ingredient |
| 07/07/2005 | WO2005061454A1 Agent or method for treatment for severe aphasia in chronic-stage cerebrovascular disorder |
| 07/07/2005 | WO2005061000A1 Remedy for angitis |
| 07/07/2005 | WO2005060975A1 Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
| 07/07/2005 | WO2005037839A8 Norcantharidin derivative compounds, method for the production thereof, compositions containing said compounds and the use thereof |
| 07/07/2005 | WO2005037052A3 Binding assay with labelled bispidine variant |
| 07/07/2005 | WO2004004779A8 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 07/07/2005 | US20050148667 Highly pure (R,R)-formoterol L-tartrate composition obtained by crystallizing a first polymorph of (R,R)-formoterol L-tartrate from aqueous isopropyl alcohol |
| 07/07/2005 | US20050148664 therapy of NF-kappaB mediated diseases; mitochondrial diseases; transplantation medicine |
| 07/07/2005 | US20050148644 Ligands for Inosine-5'-monophosphate dehydrogenase; antiviral, antiinflammatory, antibiotics, transplant rejection, autoimmune disease, , antipsoriatic immunosuppressants; 3-uriedo benzyl carbamate derivatives; high potency, side effects reduction; bioavailability; antivascular hyperproliferative |
| 07/07/2005 | US20050148642 Metabotropic glutamate receptor antagonists containing a saturated oxygen- or nitrogen-containing ring or a cycloalkyl ring, e.g., N-methyl-N-neopentyl-6-[(oxetan-3-ylamino)methyl]thiazolo[3,2-a]benzimidazole-2-carboxamide, having excellent oral activity, used especially for treating neuropathic pain |
| 07/07/2005 | US20050148641 2-Methylthiazolidine-2,4-dicarboxylic acid and salts thereof for the treatment of neurodegenerative diseases |
| 07/07/2005 | US20050148638 Increasing contractile force in cardiac muscle fiber by administering a N-[(3-yloxy)-phenyl]-arylamide derivatives; modulating at the cardiac sarcomere (cardiac beta myosin) for congestive heart failure |
| 07/07/2005 | US20050148636 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/07/2005 | US20050148624 Enzyme inhibitors with isoquinolinone structures |
| 07/07/2005 | US20050148608 Chymase enzyme inhibitors for drugs in vascular systems using sulfonylurea derivatives |
| 07/07/2005 | US20050148607 Administering to show overactivation or expression from diagnosis of diseases, immunoassay, anticancer agents or skin disorders |
| 07/07/2005 | US20050148604 Increase the intracellular cAMP level and further inhibit the activation of T cells; allergic diseases, inflammatory or immunological diseases |
| 07/07/2005 | US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof |
| 07/07/2005 | US20050148582 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 07/07/2005 | US20050148575 (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury |
| 07/07/2005 | US20050148566 Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same |
| 07/07/2005 | US20050148550 Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds |
| 07/07/2005 | US20050148527 Catalytic nucleic acids; ribozymes; translation inhibition; gene expression inhibition; for treating cardiovascular disease; for neovascularization induction in heart tissue |
| 07/07/2005 | US20050148526 Methods of obtaining isoform specific expression in mammalian cells |
| 07/07/2005 | US20050148521 Coadministration with non-steroidal antiinflammatory agent allows for lower dosage of cyclophosphamide; side effect reduction; kits |
| 07/07/2005 | US20050148515 Peptidomimetics; determining ability to bind growth hormone secretagogue; ghrelin agonists; appetite stimulation; dietetics |
| 07/07/2005 | US20050148513 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 07/07/2005 | US20050148498 Metalloprotease inhibiting activity, in particular collagenase and gelatinase, treating humans or mammals suffering from a condition or disease related to excessive degeneration of support by a metalloprotease; treat inflammatory diseases: arthrosis, parodontosis or ulcers |
| 07/07/2005 | US20050148062 Transgenic microorganisms comprising apoptosis associated genes for use as tools in identifying modulators for prevention and treatment of cell proliferative disorders |
| 07/07/2005 | US20050148058 Protein stabilization |
| 07/07/2005 | US20050148034 Using reduced microvessel outgrowth of pluripotent stem cells as diagnostic indicator angoigenseis inhibition; antitumor agents |
| 07/07/2005 | US20050148014 Regulation of human P2Y1-like G protein-coupled receptor |
| 07/07/2005 | US20050148013 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 07/07/2005 | US20050147665 Consisting of eicosapentaenoic acid or derivative, vitamin B 12, folic acid, at a maximum daily dose of 5 mg, and vitamin B6, at a maximum daily dose of 20 mg, and optionally at least one antioxidant; treatment of psychiatric disorders; schizophrenia, Alzheimer's disease, dementia, Parkinson's disease |
| 07/07/2005 | US20050147629 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| 07/07/2005 | US20050147597 Isolating autologous mononuclear cells and transplanting locally into injured tissue |
| 07/07/2005 | US20050147592 Correcting underlying genetic defect; delivering heterologous gene encoding metabolic protein causing transduction of cells resulting in expression from transformed cell genetics |
| 07/07/2005 | US20050147583 Carbamylation to form a water soluble prodrug that has a biologically active agent linked to a water soluble non-immunogenic polymer; a hydrolyzing through carbamate bond; drug delivery; no enzymes or catalysts needed for release of acitve agent |
| 07/07/2005 | US20050147567 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 07/07/2005 | DE10356815A1 Use of an angiotensin II receptor antagonist for treating type 2 diabetes or prediabetes, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure |
| 07/07/2005 | DE102004057758A1 Synergistic composition containing arginine and folic acid, useful for treatment and prevention of e.g. arterial hypertension and arteriosclerosis |
| 07/07/2005 | DE10105038B4 Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| 07/07/2005 | CA2550843A1 Novel phenylalanine derivatives |
| 07/07/2005 | CA2550632A1 Isopeptide gap junction modulators |
| 07/07/2005 | CA2550257A1 1-akan-2-ol substituted piperazine and piperidine compounds |
| 07/07/2005 | CA2550215A1 Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| 07/07/2005 | CA2549863A1 Use of relaxin as adjuvant in the differentiation of stem cells for the reconstruction of tissues |
| 07/07/2005 | CA2549510A1 Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| 07/07/2005 | CA2549116A1 Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
| 07/07/2005 | CA2548410A1 Diphenylazetidinone derivates processing cholesterol absorption inhibitory activity |
| 07/07/2005 | CA2546943A1 Novel compounds |
| 07/06/2005 | EP1550727A1 Novel macrophage foam cell formation inhibitor fka-25 and p rocess for producing the same |
| 07/06/2005 | EP1550674A1 Chitosan-containing polysaccharide, process for producing the same and use thereof |
| 07/06/2005 | EP1550668A1 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
| 07/06/2005 | EP1550663A1 New crystalline forms of antiarrhythmic compounds |
| 07/06/2005 | EP1550660A1 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |